This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
John McCann, MD
John McCann, MD
Cancer,
Cancer - Brain,
Cancer - Breast,
Cancer - Colon,
Cancer - Esophogus,
Cancer-Gynecologic,
Cancer - Kidney,
Cancer - Leukemia,
Cancer - Lung,
Cancer - Lymphoma,
Cancer - Melanoma,
Cancer - Multiple Myeloma,
Cancer - Pancreatic,
Cancer - Prostate
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
John McCann, MD
Cancer,
Cancer - Brain,
Cancer - Breast,
Cancer - Colon,
Cancer - Esophogus,
Cancer-Gynecologic,
Cancer - Kidney,
Cancer - Leukemia,
Cancer - Lung,
Cancer - Lymphoma,
Cancer - Melanoma,
Cancer - Multiple Myeloma,
Cancer - Pancreatic,
Cancer - Prostate
- D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
-
Baystate Franklin Medical Center, 164 High Street, Greenfield, MA
The purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment of either interferon alfa-2b or ipilimumab. In this study, you will get either MK-3475 or a choice of either interferon alfa-2b or ipilimumab.
John McCann, MD
Cancer - Melanoma
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
John McCann, MD
Cancer,
Cancer - Melanoma
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Page 1 of 1 | Results 1 - 6 of 6